After a successful career as a senior scientist at Imperial College London and University College London, researching in viral oncology, Stoyan trained as a patent attorney at top tier IP firm D Young & Co, before moving in-house to Pfizer, in the UK, and then Novartis and Syngenta, in Switzerland.

Stoyan has a wealth of experience in undertaking DD work, FTO, patentability, validity & infringement opinions, IP landscape analysis, patent applications drafting and filing, global patent prosecution, life-cycle management and strategic advice.

Stoyan advises companies on the value of their existing IP portfolio and how to maximize its full potential.

One of Stoyan's particular strengths is his ability to rapidly grasp technically & scientifically demanding concepts. The ability to rapidly grasp complex technical and scientific concepts is also combined with the ability to explain these clearly and succinctly to others – especially to members of the EPO.

His success at the EPO has been recognised in the Legal 500: “New partner Stoyan Radkov specialises in high-value oppositions and appeals at the EPO, representing clients from the biotech and life sciences industries”.

• First Class - BSc Honours Degree - Microbiology, University of Reading
• PhD - Viral Oncology - Ludwig Institute for Cancer Research, St Mary's Hospital, Imperial College London
• Post-doctoral fellow - Imperial College London
• Senior CRC funded post-doctoral fellow - University College London
• Private practice IP attorney - DYoung & Co (UK), UDL (Partner - UK) and HGF (Director, UK and Basel, CH)
• In-house IP attorney - Pfizer (Sandwich, UK), Novartis (Basel, CH) and Syngenta (Basel, CH)

Biotechnology and Pharmaceuticals

• Biotechnology
• Biochemicals
• Medical Devices
• Pharmaceuticals
• Diagnosctics
• Virology
• Oncology
• Immunology
  • Vaccines
  • Antibodies
• Gene-therapy
• Molecular Biology

February 2017 - Elected as European Patent Institute Council member - United Kingdom.

2015 - Recommended in Legal 500 “New partner Stoyan Radkov specialises in high-value oppositions and appeals at the EPO, representing clients from the biotech and life sciences industries”.

2000 NATURE MEDICINE: The Latent Nuclear Antigen of Kaposisarcoma associated herpes virus targets the retinoblastoma-E2F pathway and with the oncogene H-ras transforms primary rat cells. http://www.nature.com/nm/journal/ v6/n10/abs/nm1000_1121.html

1999 JOURNAL OF VIROLOGY: Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. http://jvi.asm.org/content/73/7/5688.abstract

1997 JOURNAL OF VIROLOGY: Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. http://jvi.asm.org/content/71/11/8552.abstract

1995 ABBOTT LABORATORIES PRIZE for highest degree in School of Animal and Microbial Sciences, University of Reading.

1994 ABBOTT LABORATORIES PRIZE for academic excellence.